Continued versus Interrupted Targeted Therapy during Metastasis-Directed Stereotactic Radiotherapy: A Retrospective Multi-Center Safety and Efficacy Analysis

Tumor Analyses Reveal Squamous Transformation and Off-Target Alterations As Early Resistance Mechanisms to First-line Osimertinib in EGFR-Mutant Lung Cancer

(2020) Adam J Schoenfeld et al.   CLINICAL CANCER RESEARCH

Pattern of Recurrence Analysis in Metastatic EGFR-Mutant NSCLC Treated with Osimertinib: Implications for Consolidative Stereotactic Body Radiation Therapy

(2020) Tiantian Guo et al.   INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS

Treatment patterns and health outcomes in metastatic renal cell carcinoma patients treated with targeted systemic therapies in the UK

(2020) Robert Hawkins et al.   BMC CANCER

Toxicity of combined targeted therapy and concurrent radiotherapy in metastatic melanoma patients

(2020) Johanna S. Ziegler et al.   MELANOMA RESEARCH

The value of local consolidative therapy in Osimertinib-treated non-small cell lung cancer with oligo-residual disease

(2020) Ya Zeng et al.   Radiation Oncology

Combination of stereotactic radiotherapy and targeted therapy: patterns-of-care survey in German-speaking countries

(2019) S. G. C. Kroeze et al.   STRAHLENTHERAPIE UND ONKOLOGIE

Patterns of progression on osimertinib in EGFR T790M positive NSCLC: A Swiss cohort study

(2019) S. Schmid et al.   LUNG CANCER

Overall Survival with Osimertinib in Untreated, EGFR-Mutated Advanced NSCLC

(2019) Suresh S. Ramalingam et al.   NEW ENGLAND JOURNAL OF MEDICINE

Clinical outcome of concomitant vs interrupted BRAF inhibitor therapy during radiotherapy in melanoma patients

(2018) Markus Hecht et al.   BRITISH JOURNAL OF CANCER

Stereotactic radiation therapy in the strategy of treatment of metastatic renal cell carcinoma: A study of the Getug group

(2018) Emmanuel Meyer et al.   EUROPEAN JOURNAL OF CANCER

Overall survival in patients with BRAF-mutant melanoma receiving encorafenib plus binimetinib versus vemurafenib or encorafenib (COLUMBUS): a multicentre, open-label, randomised, phase 3 trial

(2018) Reinhard Dummer et al.   LANCET ONCOLOGY

Multisite stereotactic body radiotherapy for metastatic non-small-cell lung cancer: Delaying the need to start or change systemic therapy?

(2018) Tomas Merino Lara et al.   LUNG CANCER

Difference in toxicity reporting between patients and clinicians during systemic chemotherapy in patients with urothelial carcinoma

(2017) Ken Fukushi et al.   INTERNATIONAL JOURNAL OF UROLOGY

Phase 1 Trial of Sorafenib and Stereotactic Body Radiation Therapy for Hepatocellular Carcinoma

(2016) Anthony M. Brade et al.   INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS

Avoiding Severe Toxicity From Combined BRAF Inhibitor and Radiation Treatment: Consensus Guidelines from the Eastern Cooperative Oncology Group (ECOG)

(2016) Christopher J. Anker et al.   INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS

Pattern of Failure Analysis in Metastatic EGFR-Mutant Lung Cancer Treated with Tyrosine Kinase Inhibitors to Identify Candidates for Consolidation Stereotactic Body Radiation Therapy

(2015) Hani Al-Halabi et al.   Journal of Thoracic Oncology

Stereotactic Radiation Therapy can Safely and Durably Control Sites of Extra-Central Nervous System Oligoprogressive Disease in Anaplastic Lymphoma Kinase-Positive Lung Cancer Patients Receiving Crizotinib

(2014) Gregory N. Gan et al.   INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS

Phase II Trial of Stereotactic Body Radiation Therapy Combined With Erlotinib for Patients With Limited but Progressive Metastatic Non–Small-Cell Lung Cancer

(2014) Puneeth Iyengar et al.   JOURNAL OF CLINICAL ONCOLOGY

Local Therapy with Continued EGFR Tyrosine Kinase Inhibitor Therapy as a Treatment Strategy in EGFR-Mutant Advanced Lung Cancers That Have Developed Acquired Resistance to EGFR Tyrosine Kinase Inhibitors

(2013) Helena A. Yu et al.   Journal of Thoracic Oncology

Gefitinib Combined With Stereotactic Radiosurgery in Previously Treated Patients With Advanced Non–Small Cell Lung Cancer

(2012) Zhen Wang et al.   AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS

How cutaneous eruptions help to understand the mode of action of kinase inhibitors

(2012) R. Dummer et al.   BRITISH JOURNAL OF DERMATOLOGY

Rapid Angiogenesis Onset after Discontinuation of Sunitinib Treatment of Renal Cell Carcinoma Patients

(2012) A. W. Griffioen et al.   CLINICAL CANCER RESEARCH

Targeted Therapies for Renal Cell Carcinoma: Review of Adverse Event Management Strategies

(2012) T. Eisen et al.   JNCI-Journal of the National Cancer Institute

Local Ablative Therapy of Oligoprogressive Disease Prolongs Disease Control by Tyrosine Kinase Inhibitors in Oncogene-Addicted Non–Small-Cell Lung Cancer

(2012) Andrew J. Weickhardt et al.   Journal of Thoracic Oncology

Molecular mechanisms of lung-specific toxicity induced by epidermal growth factor receptor tyrosine kinase inhibitors

(2012) SEIICHIRO SAKAO et al.   Oncology Letters

Simultaneous anti-angiogenic therapy and single-fraction radiosurgery in clinically relevant metastases from renal cell carcinoma

(2010) Michael Staehler et al.   BJU INTERNATIONAL

A Phase I Dose-Escalation Study of Fractionated Stereotactic Radiosurgery in Combination With Gefitinib in Patients With Recurrent Malignant Gliomas

(2007) Amanda L. Schwer et al.   INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS